Exact Sciences (EXAS) Tops Q2 EPS by 9c

Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.46), $0.09 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $21.2 million versus the consensus estimate of $18.54 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Jefferies Upgrades Friedrich Vorwerk Group SE (VH2:GR) to Hold
• Macquarie cuts Macau gaming sector forecasts on weak GGR growth